Novel IKZF1 rearrangement identified in a patient with blastic plasmacytoid dendritic cell neoplasm decreased haematopoietic stem cell function and promoted plasmacytoid dendritic cell abnormality

British Journal of HaematologyEarly View LETTER TO THE EDITOR Novel IKZF1 rearrangement identified in a patient with blastic plasmacytoid dendritic cell neoplasm decreased haematopoietic stem cell function and promoted plasmacytoid dendritic cell abnormality Le Yin, Le Yin Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorQian Yu, Qian Yu Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorHuifang Zhang, Huifang Zhang Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorHongkai Zhu, Hongkai Zhu Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorZeyu Deng, Zeyu Deng Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorCheng Xing, Cheng Xing Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorPeilong Wang, Peilong Wang Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorXiangju Zeng, Xiangju Zeng Department of Outpatient, The Second Xiangya Hospital of Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorZhao Cheng, Zhao Cheng Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorYue Sheng, Yue Sheng Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorHongling Peng, Corresponding Author Hongling Peng [email protected] orcid.org/0000-0003-2770-5150 Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, China Hunan Key Laboratory of Tumor Models and Individualized Medicine, Changsha, Hunan, China Correspondence Hongling Peng, Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Email: [email protected]Search for more papers by this author Le Yin, Le Yin Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorQian Yu, Qian Yu Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorHuifang Zhang, Huifang Zhang Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorHongkai Zhu, Hongkai Zhu Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorZeyu Deng, Zeyu Deng Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorCheng Xing, Cheng Xing Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorPeilong Wang, Peilong Wang Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorXiangju Zeng, Xiangju Zeng Department of Outpatient, The Second Xiangya Hospital of Central South University, Changsha, Hunan, ChinaSearch for more papers by this authorZhao Cheng, Zhao Cheng Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorYue Sheng, Yue Sheng Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, ChinaSearch for more papers by this authorHongling Peng, Corresponding Author Hongling Peng [email protected] orcid.org/0000-0003-2770-5150 Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China Institute of Molecular Hematology, Central South University, Changsha, Hunan, China Hunan Engineering Research Center of Cell Immunotherapy for Hematopoietic Malignancies, Changsha, Hunan, China Hunan Key Laboratory of Tumor Models and Individualized Medicine, Changsha, Hunan, China Correspondence Hongling Peng, Division of Hematology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Email: [email protected]Search for more papers by this author First published: 15 April 2024 https://doi.org/10.1111/bjh.19429 Le Yin and Qian Yu contributed equally to this work and should be considered cofirst authors. Zhao Cheng, Yue Sheng and Hongling Peng contributed equally to this work and should be considered cocorresponding authors. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Supporting Information Filename Description bjh19429-sup-0001-Supinfo.docxWord 2007 document , 384.4 KB Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Jain A, Sweet K. Blastic plasmacytoid dendritic cell neoplasm. J Natl Compr Cancer Netw. 2023; 21(5): 515–521. 10.6004/jnccn.2023.7026 CASPubMedGoogle Scholar 2Menezes J, Acquadro F, Wiseman M, Gomez-Lopez G, Salgado RN, Talavera-Casanas JG, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2014; 28(4): 823–829. 10.1038/leu.2013.283 CASPubMedWeb of Science®Google Scholar 3Stenzinger A, Endris V, Pfarr N, Andrulis M, Johrens K, Klauschen F, et al. Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget. 2014; 5(15): 6404–6413. 10.18632/oncotarget.2223 PubMedGoogle Scholar 4Tokuda K, Eguchi-Ishimae M, Yagi C, Kawabe M, Moritani K, Niiya T, et al. CLTC-ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes Cancer. 2014; 53(1): 78–89. 10.1002/gcc.22119 CASPubMedWeb of Science®Google Scholar 5Gao NA, Wang XX, Sun JR, Yu WZ, Guo NJ. Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: a case report. Exp Ther Med. 2015; 9(4): 1109–1112. 10.3892/etm.2015.2236 CASPubMedWeb of Science®Google Scholar 6Cao Q, Liu F, Niu G, Xue L, Han A. Blastic plasmacytoid dendritic cell neoplasm with EWSR1 gene rearrangement. J Clin Pathol. 2014; 67(1): 90–92. 10.1136/jclinpath-2013-201792 PubMedWeb of Science®Google Scholar 7Boast B, Nunes-Santos CJ, Kuehn HS, Rosenzweig SD. Ikaros-associated diseases: from mice to humans and back again. Front Pediatr. 2021; 9:705497. 10.3389/fped.2021.705497 PubMedGoogle Scholar 8Marke R, van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2018; 103(4): 565–574. 10.3324/haematol.2017.185603 CASPubMedWeb of Science®Google Scholar 9Bastidas Torres AN, Cats D, Mei H, Fanoni D, Gliozzo J, Corti L, et al. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. Genes Chromosomes Cancer. 2020; 59(5): 295–308. 10.1002/gcc.22831 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation